In this study, we adapted primary melanoma cells bearing the BRAFV600E mutation to normoxia or hypoxia and demonstrated that induction of HO-1 limits the efficacy of Vemurafenib/PLX4032 in tumor regression. This evidence concerns the gene HMOX1 and melanoma.